Bioceltix (BCX) Q1 2026 earnings summary

Executive summary

• Continued execution of strategy focused on developing innovative veterinary cell therapies and advancing products toward commercialization.

• Key project BCX-CM-J (osteoarthritis in dogs) advanced in EMA registration; full responses submitted in May 2026, awaiting further EMA queries.

• GMP certification obtained for Wrocław facility, confirming readiness for registration, production, and future commercialization.

• Progress on new large-scale veterinary biologics manufacturing plant; environmental decision received, building permit application submitted.

• Positive long-term clinical data for BCX-CM-AD (atopic dermatitis in dogs) supports registration and commercial potential.

• Strategic steps taken for US market entry, including advisory agreement for FDA/CVM regulatory strategy.

• InnoBioVet project (cell-free biologic) received positive funding recommendation (PLN 15.1m) under EU Modern Economy Funds.

Financial highlights

• No net sales revenue in Q1 2026, consistent with pre-commercial biotech phase.

• Operating loss: PLN 5.8m in Q1 2026 (vs. PLN 3.8m Q1 2025); net loss: PLN 5.7m (vs. PLN 3.8m Q1 2025).

• Net cash outflow from operations: PLN 6.2m; total net cash outflow: PLN 7.6m.

• Cash at period end: PLN 60.8m; total assets: PLN 70.6m; equity: PLN 67.6m.

• Book value per share: PLN 12.22.

Outlook and guidance

• Focus remains on regulatory processes, risk mitigation in product registration, and production infrastructure preparation.

• Sufficient cash for at least 12 months; ongoing monitoring of funding needs and opportunities for additional grants or capital.

• Key upcoming milestones: EMA feedback for BCX-CM-J, further progress on US regulatory pathway, and advancement of new manufacturing facility.